193 related articles for article (PubMed ID: 34288927)
1. Increased activity of procoagulant factors in patients with small cell lung cancer.
Pedersen S; Kristensen AF; Falkmer U; Christiansen G; Kristensen SR
PLoS One; 2021; 16(7):e0253613. PubMed ID: 34288927
[TBL] [Abstract][Full Text] [Related]
2. Extracellular vesicle-associated procoagulant phospholipid and tissue factor activity in multiple myeloma.
Nielsen T; Kristensen SR; Gregersen H; Teodorescu EM; Christiansen G; Pedersen S
PLoS One; 2019; 14(1):e0210835. PubMed ID: 30640949
[TBL] [Abstract][Full Text] [Related]
3. Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer: A sub-study of RASTEN - A randomized trial with low molecular weight heparin.
Gezelius E; Flou Kristensen A; Bendahl PO; Hisada Y; Risom Kristensen S; Ek L; Bergman B; Wallberg M; Falkmer U; Mackman N; Pedersen S; Belting M
PLoS One; 2018; 13(11):e0207387. PubMed ID: 30412630
[TBL] [Abstract][Full Text] [Related]
4. Investigation of procoagulant activity in extracellular vesicles isolated by differential ultracentrifugation.
Nielsen T; Kristensen AF; Pedersen S; Christiansen G; Kristensen SR
J Extracell Vesicles; 2018; 7(1):1454777. PubMed ID: 29696077
[TBL] [Abstract][Full Text] [Related]
5. Lobectomy and postoperative thromboprophylaxis with enoxaparin improve blood hypercoagulability in patients with localized primary lung adenocarcinoma.
Papageorgiou C; Vandreden P; Marret E; Bonnet F; Robert F; Spyropoulos A; Galea V; Elalamy I; Hatmi M; Gerotziafas GT
Thromb Res; 2013 Nov; 132(5):584-91. PubMed ID: 24094602
[TBL] [Abstract][Full Text] [Related]
6. Fractal dimension (df) as a new structural biomarker of clot microstructure in different stages of lung cancer.
Davies NA; Harrison NK; Morris RH; Noble S; Lawrence MJ; D'Silva LA; Broome L; Brown MR; Hawkins KM; Williams PR; Davidson S; Evans PA
Thromb Haemost; 2015 Nov; 114(6):1251-9. PubMed ID: 26293709
[TBL] [Abstract][Full Text] [Related]
7. Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Patients with Lung Adenocarcinoma at Risk for Cancer-Associated Thrombosis: The Observational ROADMAP-CAT Study.
Syrigos K; Grapsa D; Sangare R; Evmorfiadis I; Larsen AK; Van Dreden P; Boura P; Charpidou A; Kotteas E; Sergentanis TN; Elalamy I; Falanga A; Gerotziafas GT
Oncologist; 2018 Nov; 23(11):1372-1381. PubMed ID: 30104289
[TBL] [Abstract][Full Text] [Related]
8. Rosuvastatin treatment decreases plasma procoagulant phospholipid activity after a VTE: A randomized controlled trial.
Ramberg C; Hindberg K; Biedermann JS; Cannegieter SC; van der Meer FJ; Snir O; Leebeek FWG; Kruip MJHA; Hansen JB; Lijfering WM
J Thromb Haemost; 2022 Apr; 20(4):877-887. PubMed ID: 34953155
[TBL] [Abstract][Full Text] [Related]
9. Circulating microparticles and the risk of thrombosis in inherited deficiencies of antithrombin, protein C and protein S.
Campello E; Spiezia L; Radu CM; Bulato C; Gavasso S; Tormene D; Woodhams B; Dalla Valle F; Simioni P
Thromb Haemost; 2016 Jan; 115(1):81-8. PubMed ID: 26354831
[TBL] [Abstract][Full Text] [Related]
10. Coagulation activation and microparticle-associated coagulant activity in cancer patients. An exploratory prospective study.
van Doormaal F; Kleinjan A; Berckmans RJ; Mackman N; Manly D; Kamphuisen PW; Richel DJ; Büller HR; Sturk A; Nieuwland R
Thromb Haemost; 2012 Jul; 108(1):160-5. PubMed ID: 22535219
[TBL] [Abstract][Full Text] [Related]
11. Prothrombotic abnormalities in patients with multiple myeloma and monoclonal gammopathy of undetermined significance.
Nielsen T; Kristensen SR; Gregersen H; Teodorescu EM; Pedersen S
Thromb Res; 2021 Jun; 202():108-118. PubMed ID: 33819778
[TBL] [Abstract][Full Text] [Related]
12. Longer procoagulant phospholipid-dependent clotting time, lower endogenous thrombin potential and higher tissue factor pathway inhibitor concentrations are associated with increased VTE occurrence in patients with newly diagnosed multiple myeloma: results of the prospective ROADMAP-MM-CAT study.
Fotiou D; Sergentanis TN; Papageorgiou L; Stamatelopoulos K; Gavriatopoulou M; Kastritis E; Psaltopoulou T; Salta S; Van Dreden P; Sangare R; Larsen AK; Terpos E; Elalamy I; Dimopoulos MA; Gerotziafas GT
Blood Cancer J; 2018 Nov; 8(11):102. PubMed ID: 30405097
[TBL] [Abstract][Full Text] [Related]
13. Extracellular vesicles exposing tissue factor for the prediction of venous thromboembolism in patients with cancer: A prospective cohort study.
van Es N; Hisada Y; Di Nisio M; Cesarman G; Kleinjan A; Mahé I; Otten HM; Kamphuisen PW; Berckmans RJ; Büller HR; Mackman N; Nieuwland R
Thromb Res; 2018 Jun; 166():54-59. PubMed ID: 29656167
[TBL] [Abstract][Full Text] [Related]
14. Circulating microparticles in carriers of prothrombin G20210A mutation.
Campello E; Spiezia L; Radu CM; Gavasso S; Zerbinati P; Woodhams B; Simioni P
Thromb Haemost; 2014 Sep; 112(3):432-7. PubMed ID: 24816676
[TBL] [Abstract][Full Text] [Related]
15. Impact of breast cancer stage, time from diagnosis and chemotherapy on plasma and cellular biomarkers of hypercoagulability.
Chaari M; Ayadi I; Rousseau A; Lefkou E; Van Dreden P; Sidibe F; Ketatni H; Galea V; Khaterchi A; Bouzguenda R; Frikha M; Ghorbal L; Daoud J; Kallel C; Quinn M; Gligorov J; Lotz JP; Hatmi M; Elalamy I; Gerotziafas GT
BMC Cancer; 2014 Dec; 14():991. PubMed ID: 25535397
[TBL] [Abstract][Full Text] [Related]
16. Procoagulant effects of lung cancer chemotherapy: impact on microparticles and cell-free DNA.
Lysov Z; Dwivedi DJ; Gould TJ; Liaw PC
Blood Coagul Fibrinolysis; 2017 Jan; 28(1):72-82. PubMed ID: 26919453
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for the diagnosis of venous thromboembolism: D-dimer, thrombin generation, procoagulant phospholipid and soluble P-selectin.
Riva N; Vella K; Hickey K; Bertù L; Zammit D; Spiteri S; Kitchen S; Makris M; Ageno W; Gatt A
J Clin Pathol; 2018 Nov; 71(11):1015-1022. PubMed ID: 30093507
[TBL] [Abstract][Full Text] [Related]
18. Procoagulant activity, but not number, of microparticles increases with age and in individuals after a single venous thromboembolism.
Owen BA; Xue A; Heit JA; Owen WG
Thromb Res; 2011 Jan; 127(1):39-46. PubMed ID: 21106230
[TBL] [Abstract][Full Text] [Related]
19. Elevated coagulation factor levels affect the tissue factor-threshold in thrombin generation.
Rietveld IM; Schreuder M; Reitsma PH; Bos MHA
Thromb Res; 2018 Dec; 172():104-109. PubMed ID: 30408635
[TBL] [Abstract][Full Text] [Related]
20. Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism.
Manly DA; Wang J; Glover SL; Kasthuri R; Liebman HA; Key NS; Mackman N
Thromb Res; 2010 Jun; 125(6):511-2. PubMed ID: 19854471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
